Norway Genomics Market Size & Outlook, 2026-2033
Global Report
Related Markets
Norway genomics market highlights
- The Norway genomics market generated a revenue of USD 148.1 million in 2025 and is expected to reach USD 402.7 million by 2033.
- The Norway market is expected to grow at a CAGR of 15.1% from 2026 to 2033.
- In terms of segment, functional genomics was the largest revenue generating application in 2025.
- Pathway Analysis is the most lucrative application segment registering the fastest growth during the forecast period.
Genomics market data book summary
| Market revenue in 2025 | USD 148.1 million |
| Market revenue in 2033 | USD 402.7 million |
| Growth rate | 15.1% (CAGR from 2026 to 2033) |
| Largest segment | Functional genomics |
| Fastest growing segment | Pathway Analysis |
| Historical data | 2021 - 2024 |
| Base year | 2025 |
| Forecast period | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Functional Genomics, Epigenomics, Pathway Analysis, Biomarker Discovery |
| Key market players worldwide | Agilent Technologies Inc, Bio-Rad Laboratories Inc, Danaher Corp, Eppendorf, Eurofins Scientific SE, Roche Holding AG ADR, GE Aerospace, Illumina Inc, Myriad Genetics Inc, Oxford Nanopore Technologies PLC, Pacific Biosciences of California Inc, Qiagen NV, Quest Diagnostics Inc, Thermo Fisher Scientific Inc, 23andMe Holding Co Class A |
Other key industry trends
- In terms of revenue, Norway accounted for 0.7% of the genomics market in 2025.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In Europe, Spain genomics market is projected to lead the regional market in terms of revenue in 2033.
- Germany is the fastest growing regional market in Europe and is projected to reach USD 2,763.3 million by 2033.
The Norwegian Sequencing Centre (NSC) was founded in 2009 to make high-throughput sequencing capabilities available to the Norwegian research community. A number of organizations, including Health South-East, the University of Oslo, and the Norwegian Research Council, have provided funding.
Furthermore, in December 2021, Illumina, Inc. announced that it is supporting Norway's Precision Medicine Study. The study aims to evaluate the effectiveness of Comprehensive Genomic Profiling (CGP) based on blood samples for cancer therapy selection.
Furthermore, increasing funding related to gene therapy in the country is expected to create growth opportunities for market growth. For instance, in December 2022, Haapaniemi group approved around USD 2 million (20m NOK) to develop a clinical trial with genome-edited T cells.
No credit card required*
Publish Date: Jan 09, 2026
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Three ways to get this data
Subscribe to the databook, customize it, or ask a question.Horizon Databook
Unlock every chart on this page and get dashboard access
- Statistics1.2M+ across all markets
- Databooks30K+ global, 120K+ country
- Companies200K+ profiles
- ExportPDF, Dashboard, XLS & PNG, licensed to cite
Customize it
Customize data as per your requirement
- AddCountries, segments, years
- RecutTo your product definition
- ExtendCompany-level detail
- OrA bespoke databook
- Turnaround5–10 working days
Ask Prism AI
A cited answer in seconds
- Corpus30,000 studies, 1.2M points
- ScopeAll markets, not just this
- CitationTraced to report & table
- HonestySays "not covered" if so
- SpeedSeconds, not days
Genomics Market Scope
Genomics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Roche Holding AG ADR | View profile | 103,605 | Grenzacherstrasse 124, Basel, Switzerland, 4070 | www.roche.com |
| GE Aerospace | View profile | 125,000 | One Financial Center, Suite 3700, Boston, MA, United States, 02111 | www.geaerospace.com |
| Thermo Fisher Scientific Inc | View profile | 122,000 | 168 Third Avenue, Waltham, MA, United States, 02451 | www.thermofisher.com |
| Danaher Corp | View profile | 63,000 | 2200 Pennsylvania Avenue, N.W., Suite 800W, Washington, DC, United States, 20037-1701 | www.danaher.com |
| Quest Diagnostics Inc | View profile | 48,000 | 500 Plaza Drive, Secaucus, NJ, United States, 07094 | www.questdiagnostics.com |
| Illumina Inc | View profile | 9,300 | 5200 Illumina Way, San Diego, CA, United States, 92122 | www.illumina.com |
| Agilent Technologies Inc | View profile | 17,700 | 5301 Stevens Creek Boulevard, Santa Clara, CA, United States, 95051 | www.agilent.com |
| Bio-Rad Laboratories Inc | View profile | 8,030 | 1000 Alfred Nobel Drive, Hercules, CA, United States, 94547 | www.bio-rad.com |
| Qiagen NV | View profile | 5,900 | Hulsterweg 82, Venlo, LI, Netherlands, 5912 PL | www.qiagen.com |
| Eurofins Scientific SE | View profile | 61,798 | 23 Val Fleuri, Luxembourg, Luxembourg, L-1526 | www.eurofins.com |
Norway Genomics Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Genomics Market Outlook will help companies and investors design strategic landscapes.
Functional Genomics was the largest segment with a revenue share of 33.42% in 2025.
Horizon Databook has segmented the Norway genomics market based on functional genomics, epigenomics, pathway analysis, biomarker discovery covering the revenue growth of each sub-segment from 2021 to 2033.
The Norwegian Sequencing Centre (NSC) was founded in 2009 to make high-throughput sequencing capabilities available to the Norwegian research community. A number of organizations, including Health South-East, the University of Oslo, and the Norwegian Research Council, have provided funding.
Furthermore, in December 2021, Illumina, Inc. announced that it is supporting Norway's Precision Medicine Study. The study aims to evaluate the effectiveness of Comprehensive Genomic Profiling (CGP) based on blood samples for cancer therapy selection.
Furthermore, increasing funding related to gene therapy in the country is expected to create growth opportunities for market growth. For instance, in December 2022, Haapaniemi group approved around USD 2 million (20m NOK) to develop a clinical trial with genome-edited T cells.
- Norway Genomics Market Application Outlook (Revenue, USD Million , 2021-2033)
- Functional Genomics
- Epigenomics
- Pathway Analysis
- Biomarker Discovery
- Others
- Norway Genomics Market Deliverable Outlook (Revenue, USD Million , 2021-2033)
- Products
- Services
- Norway Genomics Market End Use Outlook (Revenue, USD Million , 2021-2033)
- Pharmaceutical and Biotechnology Companies
- Hospitals and Clinics
- Academic and Government Institutes
- Clinical Research
- Other End Users
Reasons to subscribe to Genomics Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Genomics Market Outlook databook
- Our clientele includes a mix of Genomics Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Norway Genomics Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into Norway Genomics Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Norway Genomics Market, 2021-2033 (US$M)
Norway genomics market statistics, by application, 2021-2033 (US$M)
